SCHEMBL30656116

SCHEMBL30656116

Cc1ncsc1COc1ccc2sc(C)c(C(=O)NCC(C)(C)O)c2c1

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 5/20 0.35
EGLN1 Q9GZT9 5/20 0.35
SCN9A Q15858 4/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
AR P10275 1/20 0.32
CFTR P13569 1/20 0.32
LY96 Q9Y6Y9 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
EDNRA P25101 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656117 0.86 MEN1 (0.37) L3MBTL1PPARDPPARAEDNRATDP1
SCHEMBL30656128 0.85 EGLN2 (0.34) EGLN2EGLN1L3MBTL1PPARDPPARA
SCHEMBL30656188 0.85 ALDH1A1 (0.47) L3MBTL1
SCHEMBL26792632 0.84 ALDH1A1 (0.34) EGLN2EGLN1L3MBTL1PPARDPPARA
SCHEMBL30656219 0.84 ALDH1A1 (0.34) EGLN2EGLN1L3MBTL1PPARDPPARA
SCHEMBL30656070 0.84 ALOX5 (0.41) IRAK4
SCHEMBL24484925 0.83 GAA (0.46) L3MBTL1TDP1
SCHEMBL29629920 0.83 GAA (0.46) L3MBTL1TDP1
SCHEMBL30656161 0.83 EDNRA (0.40) PPARDPPARAEDNRA
SCHEMBL26661122 0.83 EDNRA (0.40) PPARDPPARAEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US claimed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP claimed
CN-119421879-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-11 CN claimed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO claimed
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
CN-119421879-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-11 CN disclosed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 EGLN2 2524/4885EGLN1 3044/4885SCN9A 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.